Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- AnGes MG Licenses Transdermal Formulation Technology from MEDRx
April 11, 2011
- Generic Market Share to Reach 6.1% for 2010: Fuji-Keizai
April 11, 2011
- Pharma Design Licenses Part of Its Rights to Cancer Transcription Factors to Yakult
April 4, 2011
- BI Ties Up with MorphoSys to Manufacture Biopharmaceuticals
April 4, 2011
- Oncology Strategies of Top-four Japanese Pharmaceutical Companies
April 4, 2011
- Reminyl for AD: Takeda, Janssen
April 4, 2011
- Looking Back Over a Hectic Week for Vaccines
April 4, 2011
- Prazaxa to Mainly Target CV Specialists, Neurologists: NBI
April 4, 2011
- NIBIO to Promote Development of Next-generation Adjuvants
April 4, 2011
- New Drugs May Be Approved 1 Month Earlier from April
April 4, 2011
- Kitasato Daiichi Sankyo Vaccine Co., Ltd. Inaugurated
April 4, 2011
- Restrictions on Ex-company Employees of PMDA to Remain for Now
April 4, 2011
- Tokyo District Court Holds Both Gov't, AZ Responsible in Iressa Affair
April 4, 2011
- Takeda Applies for Novel ARB Azilsartan in Japan
April 4, 2011
- ASKA Resumes Production, Shipment of Thyradin-S Tablets
April 4, 2011
- Daiichi Sankyo's Direct Xa Inhibitor Rixiana Recommended for Approval by PAC
April 4, 2011
- Damage at Fukushima Plant to Affect 3 Brands: Ajinomoto Pharm.
April 4, 2011
- Eisai Announces Approval of Halaven in Europe
April 4, 2011
- Daiichi Sankyo Resumes Production at Some Facilities
April 4, 2011
- Fingolimod Approved for MS in Europe: Novartis
April 4, 2011
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…